Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2025-08-04 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PTX 6 pages 18.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the number and type of securities to be quoted, issue dates, and related information. It references a previous Appendix 3B announcement about the securities issue. This type of document is a formal announcement related to capital changes, specifically the quotation of newly issued securities. It is not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the announcement itself, not just a notice or a report publication announcement.
2025-08-04 English
Prescient successfully completes $3 million Placement 4 pages 186.2KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the successful completion of a $3 million Placement and a total raise of $9.8 million including a Share Purchase Plan. It details the use of funds, share issue price, expected allotment date, and provides background on the company's clinical development programs. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an update on capital raising activities and financing, not a full financial report or earnings release. It fits the definition of a Capital/Financing Update (CAP) as it provides information on fundraising and capital structure changes.
2025-07-30 English
Proposed issue of securities - PTX 5 pages 17.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed placement or other type of securities issue by Prescient Therapeutics Limited. It includes specifics such as the number of securities to be issued, issue price, proposed issue date, fees to brokers, and regulatory compliance details under ASX Listing Rules. This type of document is a formal announcement related to capital raising activities and changes in the company's capital structure. It is not a full financial report, earnings release, or management discussion, but rather an update on financing activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length and detail support a high confidence in this classification.
2025-07-30 English
June 2025 Quarterly Update and Appendix 4C 10 pages 373.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'June 2025 Activities Report and Appendix 4C' and includes detailed quarterly financial information such as cash flow statements, cash reserves, operating expenditures, and payments to related parties. It also discusses operational highlights, clinical trial progress, director appointments, and capital raising activities (Share Purchase Plan). The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly report. The document contains substantive financial data and analysis for the quarter ended 30 June 2025, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2025
2025-07-29 English
Trading Halt 2 pages 337.3KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Prescient Therapeutics Limited regarding a trading halt requested pending the release of an announcement related to a capital raise. It is a short notice explaining the halt and the expected timing of the announcement. There are no financial statements, detailed financial data, or report content included. The document serves as a regulatory announcement about trading status rather than a financial report or detailed disclosure. According to the rules, such short announcements about trading halts or pending announcements fall under Regulatory Filings (RNS) as a fallback category for miscellaneous regulatory announcements that do not fit other categories.
2025-07-28 English
Prescient announces results of SPP & Launches Placement 4 pages 237.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Prescient Therapeutics regarding the results of a Share Purchase Plan (SPP) and a follow-on Placement to sophisticated and professional investors. It details the amount raised ($6.8 million), the purpose of the funds (advancing clinical development of PTX-100), and the terms of the Placement including pricing and trading halt information. There are no financial statements, detailed financial analysis, or comprehensive reporting of financial results. The document is focused on capital raising activities and share issuance information. It does not contain quarterly or annual financial results, audit information, or management discussion of financial performance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is not a brief announcement or a simple report publication notice. Hence, the classification is CAP with high confidence.
2025-07-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.